ClinicalTrials.gg
Not yet recruitingNCT07596524Updated May 19, 2026

Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

An observational study in Lung Cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting at 3 sites in China. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
300
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 10 open to participants now, 11 under way, none of them phase 3. Lung Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Started
2026
with 1 other
Observational
6 of 19
4 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
18th of 19
by date

Among the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is one of 2 that started in 2026, is one of 6 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 18th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns. It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies. Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence. This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.

03

Conditions studied

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital-based

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging.
  • Previously received advanced treatment based on drugs.
  • Has a medical record of disease progression during the first-line treatment.
  • Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.

Exclusion criteria

Exclusion Criteria:

  • treatment with drugs was ≤ 2 cycles.
  • Excluding patients with incomplete key baseline and treatment information.
  • Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observation

    Patients with advanced NSCLC who have received standard first-line immune checkpoint inhibitor therapy and have experienced disease progression. Retrospective case screening and collection were conducted, and follow-up observations were carried out.

    Other: Observation

Interventions

  • OtherObservation

    The patients' second-line treatment received and the follow-up observations were retrospectively collected.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    The overall survival time of the patients enrolled.

    Time frame: Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months

  2. Progression Free Survival

    The time of disease progression free survival.

    Time frame: Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months

Secondary outcomes

  1. Objective Response Rate

    Overall response rate

    Time frame: From 2nd line treatment initiation, assessed up to 24 months

  2. Disease control rate

    Disease control rate

    Time frame: From 2nd line treatment initiation, assessed up to 24 months

  3. Immune-related adverse events

    Immune-related adverse events

    Time frame: From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months

07

Study locations

3 sites
  • Cancer Hospirtal, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen
    Shenzhen, Guangdong 518116, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
08

References and documents

Individual participant data

Plan to share: Undecided — Whether IPD will be provided will be determined by the results of subsequent clinical trials. At present, it is impossible to determine.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596524
Responsible party
JIANCHUN DUAN (Chief physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
May 19, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Jianchun Duan, M.D.
Contact
duanjianchun79@163.com
+8610-87788029
Jianchun Duan, M.D.
principal investigator · Cancer Hospirtal Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion